Research programme: DMT1 inhibitors - Xenon Pharmaceuticals
Alternative Names: Iron 1; XEN600; XEN600 seriesLatest Information Update: 04 Nov 2017
At a glance
- Originator Xenon Pharmaceuticals
- Class Small molecules
- Mechanism of Action SLC11A2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Iron overload
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Iron-overload in Canada (PO)
- 02 Jun 2010 Preclinical development is ongoing in Canada
- 20 Sep 2005 This programme is still in active development - BIO 2005: Annual International Convention (BIO-2005)